Pancreatic Cancer Research

ResearcherSt. Marianna University School of MedicineActive in the last 2 years

Kumiko Umemoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8901-7332; OpenAlex author ID A5062757390. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
82
Papers, trials and grants by year

2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 13

  1. Diagnostic performance of droplet digital PCR for KRAS mutation analysis in pancreatic cancer cytology specimens. Co-author DOI 10.1007/s00535-026-02447-9↗
  2. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  3. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  4. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  5. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  6. Quality-of-life survey of pancreatic cancer patients: a comparison between general public and physicians. Co-author DOI 10.3389/frhs.2024.1275496↗
  7. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  8. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  9. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Co-author DOI 10.1007/s00280-020-04206-w↗
  10. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2021.103465↗
  11. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  12. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort… Co-author DOI 10.1007/s00280-020-04110-3↗
  13. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001484↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 10 shared papers, 2020–2025 · strength 1.38
  2. Masafumi Ikeda · 8 shared papers, 2020–2025 · strength 1.08
  3. Chigusa Morizane · 6 shared papers, 2021–2025 · strength 0.90
  4. Naohiro Okano · 6 shared papers, 2022–2025 · strength 0.90
  5. Yu Sunakawa · 4 shared papers, 2021–2026 · strength 0.83
  6. Junji Furuse · 6 shared papers, 2021–2025 · strength 0.82
  7. Yasuyuki Kawamoto · 5 shared papers, 2023–2025 · strength 0.79
  8. Hiroshi Imaoka · 6 shared papers, 2020–2025 · strength 0.79
  9. Satoshi Kobayashi · 5 shared papers, 2020–2025 · strength 0.70
  10. Takeshi Terashima · 4 shared papers, 2021–2025 · strength 0.62
  11. Kunihiro Tsuji · 4 shared papers, 2022–2025 · strength 0.61
  12. Masato Ozaka · 4 shared papers, 2020–2025 · strength 0.53
  13. Nobumasa Mizuno · 4 shared papers, 2021–2024 · strength 0.49
  14. Akinori Asagi · 3 shared papers, 2024–2025 · strength 0.48
  15. Yohei Kitano · 3 shared papers, 2022–2025 · strength 0.43
  16. Rei Suzuki · 3 shared papers, 2022–2025 · strength 0.43
  17. Hiroyuki Takeda · 2 shared papers, 2024–2026 · strength 0.42
  18. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  19. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32
  20. Toshifumi Doi · 2 shared papers, 2025 · strength 0.32
  21. Reiko Ashida · 2 shared papers, 2025 · strength 0.32
  22. Kohei Nakachi · 2 shared papers, 2025 · strength 0.32
  23. Hiroaki Nagano · 2 shared papers, 2025 · strength 0.32
  24. Akihiro Ohba · 2 shared papers, 2025 · strength 0.32
  25. Noritoshi Kobayashi · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.